Molecular Chaperones in Periodontal Disease Treatment
Author Information
Author(s): Shamaei-Tousi Alireza, D'Aiuto Francesco, Nibali Luigi, Steptoe Andrew, Coates Anthony R. M., Parkar Mohamed, Donos Nikos, Henderson Brian
Primary Institution: University College London
Hypothesis
How do levels of circulating molecular chaperones relate to the presence and changes in local and systemic inflammation in periodontal disease?
Conclusion
Treatment of periodontal disease leads to an increase in circulating levels of HSP10, suggesting its role in controlling periodontal inflammation.
Supporting Evidence
- Periodontal patients had significantly lower levels of HSP10 and BiP compared to controls.
- Treatment increased plasma levels of HSP10 after therapy.
- HSP10 levels correlated with clinical improvement in periodontal health.
Takeaway
When people have gum disease, certain proteins in their blood that help reduce inflammation are lower, but treating the gum disease can help bring those protein levels back up.
Methodology
Patients with periodontitis and matched controls were examined, and plasma levels of HSP10, HSP60, and BiP were measured by immunoassay at baseline, 1 day, and 6 months after treatment.
Potential Biases
Potential selection bias in choosing control subjects from different clinics.
Limitations
The study did not account for all potential confounding factors that could influence molecular chaperone levels.
Participant Demographics
80 patients with moderate to severe periodontitis and 48 matched controls, similar in age, gender, ethnicity, and smoking habits.
Statistical Information
P-Value
<0.0001
Confidence Interval
95% CI 332.4–499.1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website